[{"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-001", "question": "A 45-year-old man with a history of relapsing-remitting multiple sclerosis presents with acute onset of bilateral leg weakness and urinary retention. MRI shows a new T2-hyperintense lesion at T10 with gadolinium enhancement. Despite high-dose intravenous methylprednisolone, symptoms worsen over 48 hours. CSF analysis reveals elevated IgG index and oligoclonal bands. What is the most appropriate next step in management?", "options": ["Initiate plasma exchange", "Administer rituximab", "Start fingolimod", "Perform lumbar puncture for repeat CSF analysis", "Switch to natalizumab"], "answer": "A", "answer_index": 0, "explanation": "Plasma exchange is the most appropriate next step for severe acute demyelinating attacks unresponsive to corticosteroids in multiple sclerosis, as it rapidly removes circulating autoantibodies and inflammatory mediators. Rituximab and natalizumab are disease-modifying therapies not indicated for acute management, while fingolimod is contraindicated in active inflammation; repeat CSF analysis is unnecessary with established diagnosis.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: acute severe myelitis (bilateral leg weakness, urinary retention) with MRI lesion at T10, gadolinium enhancement, and clinical deterioration despite high-dose IV methylprednisolone. CSF shows oligoclonal bands and elevated IgG index consistent with MS. The vignette describes a steroid-refractory acute demyelinating attack. Main logical issue: None; the stem provides sufficient detail to identify a single best next step. Main medical accuracy issue: None; plasma exchange is guideline-supported for severe steroid-refractory MS relapses. Minimal fix: None required.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: acute severe myelitis (bilateral leg weakness, urinary retention) with MRI lesion at T10, gadolinium enhancement, and clinical deterioration despite high-dose IV methylprednisolone. CSF shows oligoclonal bands and elevated IgG index consistent with MS. The vignette describes a steroid-refractory acute demyelinating attack. Main logical issue: None; the stem provides sufficient detail to identify a single best next step. Main medical accuracy issue: None; plasma exchange is guideline-supported for severe steroid-refractory MS relapses. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-002", "question": "A 62-year-old woman with incomplete tetraplegia from a C5 spinal cord injury undergoes inpatient rehabilitation. She develops orthostatic hypotension during tilt table training, with blood pressure dropping from 120/80 mmHg supine to 85/50 mmHg at 60 degrees. Heart rate increases minimally. Autonomic testing shows absent sympathetic skin response below the lesion. What is the most effective pharmacologic intervention to facilitate upright tolerance?", "options": ["Midodrine", "Fludrocortisone", "Propranolol", "Clonidine", "Ephedrine"], "answer": "A", "answer_index": 0, "explanation": "Midodrine, an alpha-1 agonist, is the most effective for neurogenic orthostatic hypotension in spinal cord injury by promoting vasoconstriction without significant supine hypertension risk. Fludrocortisone causes fluid retention but risks edema; propranolol and clonidine may worsen hypotension, while ephedrine is less selective and has more side effects.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. Key stem clues—C5 incomplete tetraplegia, absent sympathetic skin response below the lesion, orthostatic BP drop (120/80→85/50 mmHg) with minimal HR increase—exclusively point to neurogenic orthostatic hypotension from impaired sympathetic vasoconstriction. Midodrine, a selective oral alpha-1 agonist, directly restores vascular tone and is the most effective, guideline-endorsed first-line agent for neurogenic OH after SCI. Fludrocortisone offers indirect volume expansion but risks edema and lacks rapid vasopressor effect; propranolol and clonidine would worsen hypotension via reduced cardiac output or central sympathetic inhibition; ephedrine is nonselective with higher arrhythmia/CNS liability. The item contains no contradictions, provides sufficient discriminators for a single best answer, and the key matches consensus. Medical accuracy is high—midodrine’s efficacy and side-effect profile are correctly described, though the rationale could mention that supine hypertension still requires routine monitoring. Logical validity: true. Minimal fix: None required; optional clarification that midodrine should be titrated with supine BP monitoring.\",\"medical_accuracy_score\":4,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues—C5 incomplete tetraplegia, absent sympathetic skin response below the lesion, orthostatic BP drop (120/80→85/50 mmHg) with minimal HR increase—exclusively point to neurogenic orthostatic hypotension from impaired sympathetic vasoconstriction. Midodrine, a selective oral alpha-1 agonist, directly restores vascular tone and is the most effective, guideline-endorsed first-line agent for neurogenic OH after SCI. Fludrocortisone offers indirect volume expansion but risks edema and lacks rapid vasopressor effect; propranolol and clonidine would worsen hypotension via reduced cardiac output or central sympathetic inhibition; ephedrine is nonselective with higher arrhythmia/CNS liability. The item contains no contradictions, provides sufficient discriminators for a single best answer, and the key matches consensus. Medical accuracy is high—midodrine’s efficacy and side-effect profile are correctly described, though the rationale could mention that supine hypertension still requires routine monitoring. Logical validity: true. Minimal fix: None required; optional clarification that midodrine should be titrated with supine BP monitoring.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-003", "question": "A 28-year-old woman presents with recurrent episodes of vertigo, tinnitus, and fluctuating hearing loss, now with superimposed gait instability. MRI reveals bilateral vestibular schwannomas and a spinal ependymoma. Genetic testing confirms NF2 mutation. She develops progressive bilateral facial weakness. What is the most appropriate targeted therapy to consider for tumor stabilization?", "options": ["Bevacizumab", "Everolimus", "Crizotinib", "Trametinib", "Sorafenib"], "answer": "A", "answer_index": 0, "explanation": "Bevacizumab, a VEGF inhibitor, is the most appropriate for NF2-associated schwannomas by reducing tumor vascularity and stabilizing growth, with evidence from clinical trials showing hearing preservation. Everolimus targets mTOR but lacks specificity for NF2; crizotinib, trametinib, and sorafenib are not indicated for this condition and target unrelated pathways.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: The stem confirms NF2 mutation with bilateral vestibular schwannomas manifesting as recurrent vertigo, tinnitus, fluctuating hearing loss, and progressive bilateral facial weakness—the classic phenotype where VEGF overexpression drives tumor growth. The additional spinal ependymoma reinforces the NF2 diagnosis. Main logical issue(s): None; the question frame is precise, and bevacizumab is uniquely supported by prospective clinical data for NF2-associated schwannomas. Distractors are readily excluded: everolimus (mTOR inhibitor) lacks phase III evidence, while crizotinib (ALK/ROS1/MET), trametinib (MEK), and sorafenib (multi-kinase) target unrelated oncogenic pathways without relevance to NF2 pathophysiology. Main medical accuracy issue(s): None; the item accurately reflects current neuro-oncology consensus that bevacizumab is the first-line targeted therapy for progressive NF2 tumors, with demonstrated efficacy in tumor control and hearing preservation. Minimal fix: Not required; the item is clinically accurate, board-relevant, and requires no modification.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: The stem confirms NF2 mutation with bilateral vestibular schwannomas manifesting as recurrent vertigo, tinnitus, fluctuating hearing loss, and progressive bilateral facial weakness—the classic phenotype where VEGF overexpression drives tumor growth. The additional spinal ependymoma reinforces the NF2 diagnosis. Main logical issue(s): None; the question frame is precise, and bevacizumab is uniquely supported by prospective clinical data for NF2-associated schwannomas. Distractors are readily excluded: everolimus (mTOR inhibitor) lacks phase III evidence, while crizotinib (ALK/ROS1/MET), trametinib (MEK), and sorafenib (multi-kinase) target unrelated oncogenic pathways without relevance to NF2 pathophysiology. Main medical accuracy issue(s): None; the item accurately reflects current neuro-oncology consensus that bevacizumab is the first-line targeted therapy for progressive NF2 tumors, with demonstrated efficacy in tumor control and hearing preservation. Minimal fix: Not required; the item is clinically accurate, board-relevant, and requires no modification.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-004", "question": "A 55-year-old man with diabetic amyotrophy presents for outpatient rehabilitation with severe proximal leg weakness and pain. Electromyography shows denervation in the L2-L4 myotomes. Despite optimized glycemic control, he has persistent muscle atrophy. What is the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy?", "options": ["Intravenous immunoglobulin", "Pyridostigmine", "Gabapentin", "Corticosteroids", "Plasmapheresis"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin has shown benefit in diabetic amyotrophy by modulating autoimmune-mediated nerve damage, leading to improved strength and pain control in refractory cases. Corticosteroids risk worsening diabetes; pyridostigmine is for myasthenia, gabapentin addresses pain but not weakness, and plasmapheresis lacks supporting evidence.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (valid), single best answer defensible. Verdict: Correct best answer. Key stem clues—diabetic amyotrophy with painful proximal L2-L4 denervation and persistent atrophy despite optimized glycemic control—imply immune-mediated pathophysiology requiring adjunctive therapy. IVIG is the most plausible option: several small case series demonstrate modest functional gains, whereas alternatives are clearly mismatched (pyridostigmine for neuromuscular junction, gabapentin for neuropathic pain without affecting weakness, corticosteroids with unacceptable diabetes exacerbation risk, plasmapheresis lacking any supportive data). Logical structure is sound with clearly differentiated options permitting unequivocal discrimination. Medical accuracy issue: The rationale overstates IVIG's evidence base. Current literature comprises low-quality, heterogeneous studies; IVIG is not guideline-recommended, FDA-approved, or standard of care. Labeling it 'most evidence-based' misleads learners. Minimal fix: Revise stem to 'Which adjunctive therapy has the best available (though limited and investigational) evidence?' and add explicit statement in rationale that IVIG is not standard of care and requires shared decision-making.\",\"medical_accuracy_score\":3,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (valid), single best answer defensible. Verdict: Correct best answer. Key stem clues—diabetic amyotrophy with painful proximal L2-L4 denervation and persistent atrophy despite optimized glycemic control—imply immune-mediated pathophysiology requiring adjunctive therapy. IVIG is the most plausible option: several small case series demonstrate modest functional gains, whereas alternatives are clearly mismatched (pyridostigmine for neuromuscular junction, gabapentin for neuropathic pain without affecting weakness, corticosteroids with unacceptable diabetes exacerbation risk, plasmapheresis lacking any supportive data). Logical structure is sound with clearly differentiated options permitting unequivocal discrimination. Medical accuracy issue: The rationale overstates IVIG's evidence base. Current literature comprises low-quality, heterogeneous studies; IVIG is not guideline-recommended, FDA-approved, or standard of care. Labeling it 'most evidence-based' misleads learners. Minimal fix: Revise stem to 'Which adjunctive therapy has the best available (though limited and investigational) evidence?' and add explicit statement in rationale that IVIG is not standard of care and requires shared decision-making.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}]